A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Sponsored by Amgen
About this trial
Last updated 8 months ago
Study ID
20210025
Status
Active, not recruiting
Type
Interventional
Phase
Phase 4
Placebo
No
Accepting
18+ Years
Female
Not accepting
Healthy Volunteers
Trial Timing
Started 2 years ago
What is this trial about?
The primary objective of this study is to characterize safety and tolerability of
romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in
India.
What are the participation requirements?
Inclusion Criteria
- Participants diagnosed with osteoporosis who are postmenopausal and have a high risk of fracture who provided inform consent (in-person or through their legally authorized representative) to participate in the use of romosozumab per local label in India.
Exclusion Criteria
- Participants who experienced myocardial infarction or stroke within a year prior to entering this study.